Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Fennec Pharmaceuticals Inc       CA31447P1009

FENNEC PHARMACEUTICALS INC
Mes dernières consult.
Most popular
  Report  
End-of-day quote. End-of-day quote  - 09/14
12.19 USD   +1.58%
2017Fennec Announces Closing of Public Offering
GL
2017Fennec Announces Pricing of Public Offering
GL
2017Fennec Announces Proposed Public Offering of Common Shares
GL
 SummaryChartsNewsCalendarCompanyFinancialsConsensus 
Financials ($)
Sales 2017 -
EBIT 2017 -6,71 M
Net income 2017 -7,06 M
Debt 2017 -
Yield 2017 -
Sales 2018 -
EBIT 2018 -10,0 M
Net income 2018 -9,88 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 0
Capitalization 159 M
More Financials
Company
Fennec Pharmaceuticals, Inc. operates as a small stage biotechnology company.It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients.The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham,... 
More about the company
Latest news on FENNEC PHARMACEUTICALS INC
2017Fennec Announces Closing of Public Offering
GL
2017Fennec Announces Pricing of Public Offering
GL
2017Fennec Announces Proposed Public Offering of Common Shares
GL
2017Fennec Provides Business Update And Reports Third Quarter 2017 Results
GL
2017FENNEC PHARMACEUTICALS : Announces Positive Results From Phase 3 SIOPEL 6 Study ..
GL
2017Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK&trad..
GL
2017FENNEC PHARMACEUTICALS INC. (OTCMKTS : FENCF) Files An 8-K Financial Statements ..
AQ
2017FENNEC PHARMACEUTICALS : IIROC Trade Resumption - FRX
AQ
2017FENNER : IIROC Trade Resumption - Fennec Pharmaceuticals Inc.
AQ
2017FENNER : IIROC Trade Halt - Fennec Pharmaceuticals Inc.
AQ
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2017Fennec Pharma uplisted to Nasdaq Capital Market today 
2017Fennec Pharmaceuticals (FENCF) Presents At Wedbush PacGrow Healthcare Confere.. 
2017Fennec Pharmaceuticals reports Q2 results 
2017Fennec Pharma completes private $7.6M capital raise 
2017Premarket analyst action - healthcare 
Chart FENNEC PHARMACEUTICALS INC
Duration : Period :
Fennec Pharmaceuticals Inc Technical Analysis Chart | CA31447P1009 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 22,0 $
Spread / Average Target 154%
Managers
NameTitle
Rostislav C. Raykov Chief Executive Officer & Director
Khalid Islam Chairman
Robert C. Andrade Chief Financial Officer
Chris A. Rallis Independent Director
Adrian J. Haigh Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FENNEC PHARMACEUTICALS INC313.84%156
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
GENMAB4.28%11 055